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Objectives. This study sought to assess the contribution and
action of nitric oxide and endothelin-1 in peripheral resistance
vessels of patients with syndrome X.
Background. Patients with syndrome X may have a generalized
disorder of vascular and endothelial function, promoting vaso-
spasm.
Methods. Changes in blood flow responses to intrabrachial
infusion of the endothelium-dependent vasodilators substance P
and acetylcholine, the endothelium-independent nitric oxide do-
nor sodium nitroprusside and the endothelin type A (ETA)
receptor antagonist BQ-123 were assessed using venous occlusion
plethysmography in 10 patients with syndrome X and 10 matched
control subjects. Vasoconstrictor responses to the nitric oxide
synthase inhibitor L-NG-monomethyl arginine (L-NMMA) and
endothelin-1 were also determined.
Results. There were no significant differences in the responses
to acetylcholine, substance P, sodium nitroprusside or BQ-123
between patients and control subjects. However, despite similar
degrees of vasoconstriction in response to L-NMMA in both
groups, endothelin-1 caused a reduction in forearm blood flow of
only 20 6 2% in patients with syndrome X compared with 35 6 3%
in matched control subjects at 90 min (p < 0.001). Although
plasma endothelin-1 concentrations were not significantly higher
in patients with syndrome X (4.8 vs. 4.0 pg/ml, p 5 0.17), the
vasoconstriction caused by endothelin-1 infusion correlated in-
versely with plasma endothelin-1 concentrations (r 5 20.51, p 5
0.04).
Conclusions. Patients with syndrome X had normal basal and
stimulated nitric oxide activity and basal endogenous ETA
receptor-mediated vascular tone. However, despite otherwise nor-
mal vascular function, there was reduced responsiveness to exog-
enous endothelin-1, possibly reflecting overactivity of this system
and ETA receptor downregulation.
(J Am Coll Cardiol 1998;31:1585–90)
©1998 by the American College of Cardiology
Over 100 years ago, Sir William Osler described a condition of
“hysterical angina” or “pseudoangina” in patients who had
typical anginal pain but were found to have normal coronary
arteries after death (1). With the emergence of electrocardi-
ography and coronary angiography, this condition became
known as syndrome X (2). The precise definition of this
syndrome varies among centers and clinicians. However, a
relatively homogeneous group of patients can be defined on
the basis of typical anginal chest pain, a positive exercise
tolerance test and a normal coronary angiogram (3,4).
Results from several major studies suggest that within
syndrome X there is a substantial subgroup of patients with
abnormal vascular responses. Various investigators have doc-
umented impaired coronary vascular reserve with abnormal
responses to vasodilators (5–8) and to atrial pacing (9,10).
Some investigators (11) have postulated that in this subgroup
of patients with syndrome X, the chest pain is a consequence of
increased coronary resistance vessel tone leading to ischemic
pain—so-called “microvascular angina”—and that this may be
due to endothelial dysfunction (6,8,12). Evidence in favor of an
ischemic origin of the chest pain in syndrome X arises from
histologic abnormalities seen in myocardial biopsies (13), the
reduction of myocardial blood flow (by positron emission
tomography and thallium scanning) (7,13,14) and the identifi-
cation of elevated coronary sinus lactate concentrations (10).
Moreover, the vascular abnormalities of syndrome X are not
confined to the coronary circulation because impaired reactive
hyperemia to forearm ischemia (12) and structural alterations
in the small arteries of the skin and subcutaneous tissue (15)
have been detected. Therefore, there may be a generalized
dysfunction of vascular or endothelial function, as opposed to
a local coronary abnormality, in syndrome X.
Both the nitric oxide and endothelin systems contribute to
the maintenance of basal peripheral vascular tone in humans
(16,17). The aim of the current study was to assess the
contribution and action of nitric oxide and endothelin-1 in
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peripheral resistance vessels of patients with syndrome X. The
peripheral vascular actions of endogenous and exogenous
nitric oxide and endothelin-1 were determined using the nitric
oxide synthase inhibitor, L-NG-monomethyl arginine (L-
NMMA), the nitric oxide donor, sodium nitroprusside, the
endothelin type A (ETA) receptor antagonist, BQ-123, and
endothelin-1 peptide. In addition, endothelial cell function was
assessed using the endothelium-dependent, nitric oxide–
generating vasodilators, substance P and acetylcholine (18).
Methods
Patients. Patients with syndrome X were recruited accord-
ing to the criteria in Table 1 and were matched by age and
gender with healthy control subjects. The patients had under-
gone coronary angiography and exercise treadmill tests within
12 months of the study and were considered to have normal
smooth coronary arteries on angiography by two independent
cardiologists. All subjects attended a screening visit and re-
ceived a clinical examination, rest electrocardiogram (ECG),
echocardiogram and oral glucose tolerance test. Control sub-
jects did not have a history of chest pain or clinically significant
disease and had a normal rest ECG and echocardiogram.
Studies were undertaken with the approval of the Lothian
Research Ethics Committee and were in accordance with the
Declaration of Helsinki. Each subject gave written informed
consent before entry into the study.
Assays. Plasma endothelin-1 (Peninsula Laboratories Eu-
rope Ltd., St. Helens, United Kingdom) and big endothelin-1
(Peninsula Laboratories Europe Ltd.) were determined by
radioimmunoassay (19); von Willebrand factor (vWF) antigen
(Dako A/S, Glostrup, Denmark) and insulin (Boehringer
Mannheim GmbH Diagnostica, Mannheim, Germany) by an
enzyme-linked immunosorbent assay; and nonesterified fatty
acid (Wako, Neuss, Germany), triglyceride (Boehringer Mann-
heim GmbH Diagnostica, Mannheim, Germany) and choles-
terol (Boehringer Mannheim GmbH Diagnostica, Mannheim,
Germany) by an enzymatic colorimetric method. Low density
lipoprotein cholesterol was determined by the method of
Friedewald et al. (20).
Study design. Blood flow was measured in both forearms
by venous occlusion plethysmography using mercury-in-Silastic
strain gauges applied to the widest part of the forearm, as
described previously (17,21). Blood pressure was monitored in
the noninfused arm at intervals throughout each study using a
semiautomated, noninvasive oscillometric sphygmomanometer
(22) (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).
The brachial artery of the nondominant arm was cannulated
with a 27-standard wire gauge steel needle (Cooper’s Needle
Works Ltd., Birmingham, United Kingdom) under 1% lido-
caine (xylocaine; Astra Pharmaceuticals Ltd., Kings Langley,
United Kingdom) local anesthesia. The total rate of intraarte-
rial infusions was maintained constant throughout all studies at
1 ml/min. Substance P (Clinalfa AG, La¨ufelfingen, Switzer-
land), sodium nitroprusside (Nipride; Roche, Welwyn Garden
City, United Kingdom), acetylcholine (Miochol; Iolab, Brack-
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ECG 5 electrocardiogram
ETA receptor 5 endothelin type A receptor
ETB receptor 5 endothelin type B receptor
L-NMMA 5 L-NG-monomethyl arginine
vWF 5 von Willebrand factor
Table 1. Inclusion and Exclusion Criteria for Study
Inclusion Criteria Exclusion Criteria
Age between 21 and 75 years Hypertension (systolic blood pressure .160 mm Hg or
diastolic blood pressure .90 mm Hg)
Typical anginal chest pain Diabetes mellitus
Echocardiography
$2-mm horizontal or downsloping ST segment
depression (60 ms after the J point) on exercise
treadmill testing using the Bruce protocol
Left ventricular hypertrophy (.1.3-mm thickness
of posterior wall of left ventricle)
Regional wall motion abnormalities
Valvular heart disease (trivial mitral
Angiographically normal smooth coronary arteries incompetence was permitted)
Impaired ventricular function
Electrocardiography
Left ventricular hypertrophy (.35 mm from
summation of amplitude of S wave in lead V1
and R wave in lead V5 or V6)
Left bundle branch block
Pathologic Q waves or T wave inversion
Any evidence of coronary artery atherosclerosis
Previous myocardial infarction
History of dyspepsia, peripheral vascular disease or
cerebrovascular disease
Other significant cardiac disease
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nell, United Kingdom), L-NMMA (Clinalfa AG), endothelin-1
(Clinalfa AG) and BQ-123 (American Peptide Company) were
administered after dissolution in 0.9% saline (Baxter Health-
care Ltd., Thetford, United Kingdom). Before the subjects
underwent each of the studies, aspirin was discontinued for 10
days and vasoactive or nonsteroidal anti-inflammatory drugs
for at least 5 half-lives. All subjects abstained from alcohol for
24 h and from food and caffeinated drinks for at least 5 h
before each study. Subjects rested recumbent in a quiet,
temperature-controlled room maintained at 23.5 to 24.5°C.
Before participating in one of the following protocols, saline
was infused for the first 30 min to allow time for equilibration,
with forearm blood flow measured every 10 min and the final
measurement taken as basal blood flow.
Nitric oxide system. In 10 patients with syndrome X and 10
age- and gender-matched control subjects, intrabrachial sub-
stance P was administered at 1, 2 and 4 pmol/min (18,23);
sodium nitroprusside at 5, 15 and 30 nmol/min (23); and
acetylcholine at 27.5, 55 and 110 nmol/min (16,18,23) for 6 min
at each dose. Administration of the three agents was separated
by 20-min saline infusions and given in random order. Finally,
after a further 20-min saline infusion, L-NMMA was adminis-
tered at 4 mmol/min (16,18) for 10 min. Forearm blood flow
measurements were made for the last 3 min of each infusion
period.
Endothelin system. In 10 patients with syndrome X and 10
age- and gender-matched control subjects, intrabrachial BQ-
123 was administered at 10 nmol/min (17) for 90 min. On a
separate study day, at least 1 month later, endothelin-1 was
administered at 5 pmol/min (17) for 90 min. Forearm blood
flow measurements were made for 3 min every 6 min.
All subjects were not able to attend both the nitric oxide
and endothelin studies; five patients and nine control subjects
were common to both phases.
Data analysis and statistics. Study group size, based on
reproducibility data derived from forearm resistance vessel
responses to endothelin-1, gave a 90% power to detect a 24%
difference in blood flow responses at a significance level of 5%.
Data were examined, as appropriate, by two-way analysis of
variance (ANOVA) with repeated measures, the two-tailed
unpaired Student t test and regression analysis using Excel
version 5.0 (Microsoft). All results are expressed as the mean
value 6 SEM. Statistical significance was set at the 5% level.
Results
Subject characteristics. Patients with syndrome X were
well matched with control subjects for age, gender and serum
lipid and thyroid profiles (Table 2). The rest ECG was normal
in both patients and control subjects, with no baseline ST
Table 2. Characteristics of Study Group













Age (years) 56 6 1 55 6 3 56 6 2 54 6 3 54 6 3 55 6 4
Gender (M/F) 4/11 4/7 4/6 4/6 3/7 3/7
Body mass index (kg/m2) 28 6 1 25 6 1* 28 6 2 25 6 1* 28 6 2 25 6 1*
Blood pressure (mm Hg)
Systolic 138 6 4 127 6 3 139 6 5 127 6 3 137 6 4 128 6 3
Diastolic 78 6 1 77 6 2 79 6 2 77 6 2 79 6 2 78 6 2
Heart rate (beats/min) 71 6 1 70 6 1 70 6 1 70 6 1 70 6 1 70 6 1
ST segment depression during treadmill exercise
testing (mm)
2.7 6 0.2 — 2.6 6 0.2 — 2.7 6 0.1 —
Plasma endothelin-1 (pg/ml) 4.8 6 0.5 4.0 6 0.2 4.5 6 0.6 4.0 6 0.2 4.8 6 0.5 4.0 6 0.3
Plasma big endothelin-1 (pg/ml) 20 6 2 18 6 2 17 6 0.7 18 6 1.7 20 6 1.5 19 6 1.9
Plasma vWF (IU/ml) 1.17 6 0.12 0.98 6 0.05 1.13 6 0.16 0.97 6 0.05 1.3 6 0.2 0.98 6 0.05
Total cholesterol (mg/dl) 258 6 15 268 6 23 260 6 21 257 6 23 258 6 23 276 6 24
LDL cholesterol (mg/dl) 174 6 13 197 6 22 175 6 18 186 6 22 178 6 19 202 6 24
HDL cholesterol (mg/dl) 55 6 4 47 6 5 58 6 5 47 6 5 50 6 5 49 6 5
Triglycerides (mg/dl) 141 6 15 120 6 22 134 6 18 121 6 24 146 6 19 124 6 25
Oral glucose tolerance
Fasting glucose (mmol/liter) 4.9 6 0.2 4.9 6 0.2 5.0 6 0.2 4.9 6 0.1 5.0 6 0.1 4.9 6 0.2
2-h glucose (mmol/liter) 5.1 6 0.4 5.2 6 0.4 5.0 6 0.4 4.9 6 0.4 5.2 6 0.5 5.4 6 0.4
Fasting insulin (IU/ml) 8.9 6 1.5 10.9 6 2.7 7.2 6 1.3 9.7 6 2.7 9.9 6 2.1 11.6 6 2.9
2-h insulin (IU/ml) 45.3 6 14.5 25.8 6 5.9 36.5 6 15 22.6 6 5.6 59.0 6 22.5 28.0 6 6.1
Fasting NEFA (mEq/liter) 584 6 71 572 6 76 541 6 60 550 6 81 626 6 108 604 6 77
2-h NEFA (mEq/liter) 26 6 12 33 6 13 29 6 17 36 6 14 32 6 18 36 6 14
Thyroid stimulating hormone (mU/liter) 2.0 6 0.6 1.3 6 0.3 2.0 6 0.6 1.4 6 0.3 2.5 6 0.8 1.2 6 0.2
Thyroxine (pmol/liter) 15.2 6 0.9 15.3 6 0.8 15.1 6 1.0 15.3 6 0.8 14.9 6 1.0 15.6 6 0.8
Urea (mmol/liter) 5.8 6 0.3 5.2 6 0.3 5.8 6 0.3 5.2 6 0.3 5.8 6 0.4 5.1 6 0.4
*p 5 0.02 (unpaired t test). Data are presented as mean value 6 SD. F 5 female; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; M 5 male;
NEFA 5 nonesterified fatty acids; Pts 5 patients; vWF 5 von Willebrand factor.
1587JACC Vol. 31, No. 7 NEWBY ET AL.
June 1998:1585–90 ENDOTHELIN-1 AND NITRIC OXIDE IN SYNDROME X
segment changes. Body mass index was significantly higher in
the patients with syndrome X (p 5 0.02), with a trend (0.10 .
p . 0.05) toward higher systolic blood pressures and 2-h
plasma insulin concentrations. There were no significant dif-
ferences in other hemodynamic or metabolic variables. There
were no significant differences in mean plasma vWF (p 5
0.16), endothelin-1 (p 5 0.17) or big endothelin-1 concentra-
tions (p 5 0.58).
Nitric oxide system. There were no significant differences
in length (25.4 6 0.7 vs. 25.2 6 0.7 cm) or basal blood flow
(3.8 6 0.4 [range 2.9 to 9.2] vs. 3.3 6 0.5 [range 1.0 to 6.3]
ml/100 ml per min) of the infused forearm in patients with
syndrome X versus control subjects (24). There were no
significant changes in blood pressure, heart rate or blood flow
in the noninfused forearm during the course of the studies.
Substance P, acetylcholine and sodium nitroprusside all
caused dose-dependent vasodilation in the infused forearm
(p , 0.001 for all) (Fig. 1). L-NMMA caused a 36.7 6 3.4%
(p , 0.001) and 38.4 6 3.1% (p 5 0.007) reduction in forearm
blood flow in patients with syndrome X and control subjects,
respectively. There were no significant differences in the blood
flow responses to substance P, acetylcholine, sodium nitroprus-
side or L-NMMA between patients and control subjects.
Endothelin system. There were no significant differences in
basal blood flow of the infused forearm on the endothelin-1
(3.5 6 0.8 [range 2.3 to 6.2] vs. 4.2 6 0.5 [range 1.8 to 10.2]
ml/100 ml per min) and BQ-123 (3.2 6 0.9 [range 1.7 to 6.4] vs.
4.1 6 0.5 [range 1.0 to 10.0] ml/100 ml per min) study days in
patients with syndrome X versus control subjects. There were
no significant changes in blood pressure, heart rate or blood
flow in the noninfused forearm during the course of the
BQ-123 and endothelin-1 study days.
BQ-123 caused a progressive vasodilation (p , 0.001 by
ANOVA for both groups), which appeared to reach a maxi-
mum by 72 min (Fig. 2). At 90 min, forearm blood flow was
increased by 39 6 6% in the patients with syndrome X and
37 6 9% in the control subjects. There was no significant
difference between patients and control subjects.
Endothelin-1 caused a progressive vasoconstriction (p ,
0.001 by ANOVA for both groups), which appeared to reach a
maximum by 66 min (Fig. 2). The reduction in forearm blood
flow was significantly (p , 0.001 by two-way ANOVA) less in
the patients with syndrome X (20 6 2% [range 9% to 29%] at
90 min) than in the control subjects (35 6 3% [range 25% to
53%]) at 90 min. Using data from all subjects, the degree of
vasoconstriction produced by endothelin-1 infusion was in-
versely correlated with plasma endothelin-1 concentrations
(r 5 20.51, p 5 0.04), but the correlation with mean arterial
pressure was not significant (r 5 0.19, p 5 0.41).
Discussion
A number of previous studies have used broader criteria for
defining syndrome X, including patients with $1 mm ST
segment depression (8,25–27) and those with minor, “hemo-
dynamically nonsignificant” atherosclerotic plaques in the cor-
onary arteries (27,28). In an attempt to define a more precise
group of patients with syndrome X, we employed criteria of
$2 mm ST segment depression on exercise testing in combi-
nation with typical anginal chest pain and normal smooth
coronary arteries on angiography. Patients with other potential
causes of chest pain or with coexisting conditions associated
with microangiopathy were excluded. In agreement with pre-
vious studies (26,29), our patients with syndrome X tended to
be insulin-resistant, although they also had a larger body mass
index and tended to have a higher systolic blood pressure.
Syndrome X and endothelin-1. For the first time, to our
knowledge, we report that patients with syndrome X, as
compared with control subjects, have a reduced responsiveness
of peripheral resistance vessels to endothelin-1 despite normal
vasodilation to the ETA receptor antagonist BQ-123. In an
earlier study with a larger number of patients (n 5 40), Kaski
Figure 2. Responses in forearm blood flow to 90-min infusions of
BQ-123 (circles) and endothelin-1 (squares) in patients with syndrome
X (solid symbols) and control subjects (open symbols). p , 0.001
between patients and control subjects for endothelin-1 response.
Figure 1. Responses in forearm blood flow to incremental doses of
substance P (circles [pmolmin]), acetylcholine (squares [nmol/min])
and sodium nitroprusside (triangles [nmol/min]) in patients with
syndrome X (solid symbols) and control subjects (open symbols). There
were no significant differences between patients and control subjects.
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et al. (25) reported a significant elevation in plasma
endothelin-1 concentrations (3.8 6 1.3 vs. 2.9 6 0.7 pg/ml) in
patients versus control subjects. We did not demonstrate a
significant elevation in plasma endothelin-1 or big endothelin-1
concentrations in our patients with syndrome X, although the
magnitude was similar to the previous study and probably
reflects the fact that the study was not powered to detect such
a difference. However, interestingly, we did find an inverse
correlation between endothelin-1–induced vasoconstriction
and circulating plasma endothelin-1 concentrations. This sug-
gests that in the presence of higher endothelin-1 concentra-
tions, possibly related to increased endothelin generation,
there may be ETA receptor downregulation such that the
overall contribution of ETA receptor-mediated vascular tone
remains unchanged. Although ETA receptor downregulation
may explain the reduction in vasoconstriction to exogenous
endothelin-1, endothelin type B (ETB) receptor function may
also be important and merits further investigation. Indeed,
abnormalities of ETB receptor function have been demon-
strated in the coronary vessels of an animal model of heart
failure (30), in the peripheral resistance vessels of patients with
chronic heart failure (31) and in human atherosclerotic vessels
(32).
We have recently shown that the majority of the vasodila-
tion seen with selective ETA receptor antagonism results from
nitric oxide release (33). Given our findings of normal nitric
oxide–mediated responses in syndrome X, it may not be
surprising that the BQ-123 responses were similar in the two
groups. Thus, detecting a reduction or augmentation of endog-
enous endothelin-1–mediated vasoconstriction may be ob-
scured by the nitric oxide release seen with BQ-123.
Syndrome X and nitric oxide. Despite evidence in support
of a nitric oxide–mediated endothelial dysfunction involving
the coronary resistance vessels of patients with syndrome X
(6,8,28,34), we were unable to detect a significant abnormality
affecting normal basal and stimulated release of, and sensitivity
to, nitric oxide in the resistance vessels of the forearm circu-
lation in vivo. This is in agreement with the findings of normal
endothelium-dependent and -independent nitric oxide–
mediated vasorelaxation in structurally abnormal peripheral
resistance arteries of patients with syndrome X studied ex vivo
(15). However, in a post hoc analysis, we did find that plasma
concentrations of vWF were above the normal range (0.42 to
1.22 IU/ml) in six patients with syndrome X, but in none of the
control subjects (p , 0.01 by chi-square test). Given our
findings and those of Kaski et al. (25), it would appear that
patients with syndrome X may have a generalized endothelial
dysfunction that does not universally affect the nitric oxide
system.
Study limitations. The failure to detect differential re-
sponses to endothelium-dependent nitric oxide–mediated pe-
ripheral vascular responses may reflect the relative hypercho-
lesterolemia of the study groups. Both the patient and control
groups had relatively high mean serum cholesterol concentra-
tions, although this is consistent with the average prevailing
serum cholesterol concentrations in the Scottish population
(35). This may have conferred some degree of endothelial
dysfunction on the subjects (36) and obscured the contribution
of further dysfunction. In addition, the slow onset and offset of
action of endothelin agonists and antagonists mean that only
one dose of each agent can be administered on each study day.
Thus, a full dose-response relation cannot easily be deter-
mined. Moreover, further characterization of responses medi-
ated by the ETB receptors is now needed to further clarify this
response. There also remains the possibility that the observed
differences are related to the disparity in body mass index
between the two groups.
Conclusions. Our study suggests that despite normal over-
all peripheral resistance vessel function, there appears to be a
reduced responsiveness to endothelin-1 in patients with syn-
drome X, consistent with increased endothelin-1 production
and ETA receptor downregulation. Further studies are now
required to fully characterize the role of the endothelin system
in both the peripheral and coronary circulations in this condi-
tion.
We acknowledge the assistance of Dr. Rudolph Riemersma, Neil Johnston and
Frances Stenhouse in performing the assays.
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